Progress of research on application of oral antidiabetic agents for patients with diabetic nephropathy

doi:10.3877/cma.j.issn.2095-3216.2016.04.003

Abstract

Abstract:

Diabetic nephropathy (DN) is one of the most common causes for end-stage renal disease (ESRD) in the world. Intensive glucose control is effective in decreasing the incidence and progression of DN. As the renal function reduces, accumulation of hypoglycemic drugs can occur in the patients, which increases adverse reactions of the drugs as well as hypoglycemia events. This article mainly discussed the application of oral hypoglycemic drugs used for DN, including insulin secretagogues, non-insulin secretagogues, and other new type of oral hypoglycemic drugs.

Key words: Diabetic nephropathy, Insulin secretagogues, Non-insulin secretagogues, Oral hypoglycemic drugs, new type

Niansong Wang, Li He, Dongsheng Cheng. Progress of research on application of oral antidiabetic agents for patients with diabetic nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2016, 05(04): 155-158.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2016.04.003

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2016/V05/I04/155

References 29

[1]	Dounousi E,Duni A,Leivaditis K, et al. Improvements in the management of diabetic nephropathy[J]. Rev Diabet Stud, 2015, 12(1-2): 119-133.
[2]	Lamine F,Lalubin F,Pitteloud N, et al. Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs[J]. Swiss Med Wkly, 2016, 146: w14282.
[3]	Zoungas S,de Galan BE,Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial[J]. Diabetes Care, 2009, 32(11): 2068-2074.
[4]	Abe M,Okada K,Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice[J]. Curr Drug Metab, 2011, 12(1): 57-69.
[5]	Flynn C,Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis[J]. Nat Rev Nephrol, 2013, 9(3): 147-153.
[6]	Niemi M,Backman JT,Juntti-Patinen L, et al. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide[J]. Br J Clin Pharmacol, 2005, 60(2): 208-217.
[7]	Pernicova I,Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer[J]. Nat Rev Endocrinol, 2014, 10(3): 143-156.
[8]	Górriz JL,Nieto J,Navarro-González JF, et al. Nephroprotection by hypoglycemic agents: Do we have supporting data?[J]. J Clin Med, 2015, 4(10): 1866-1889.
[9]	Venos ES,Sigal RJ. My patient′s diabetic kidney disease has progressed to stage 4; should I discontinue metformin?[J]. Can J Diabetes, 2014, 38(5): 296-299.
[10]	Lipska KJ,Bailey CJ,Inzucchi SE. Metformin in patients with type 2 diabetes and kidney disease: a systematic review[J]. JAMA, 2014, 312(24): 2668-2675.
[11]	Ekstrom N,Schioler L,Svensson AM, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register[J]. BMJ Open, 2012, 2(4): e001076.
[12]	Lipska KJ,Bailey CJ,Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency[J]. Diabetes Care, 2011, 34(6): 1431-1437.
[13]	KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease[J]. Am J Kidney Dis, 2007, 49(2 Suppl 2): S12-S154.
[14]	Chapelsky MC,Thompson-Culkin K,Miller AK, et al. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency[J]. J Clin Pharmacol, 2003, 43(3): 252-259.
[15]	Flynn C,Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis[J]. Nat Rev Nephrol, 2013, 9(3): 147-153.
[16]	Abe M,Okada K,Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice[J]. Curr Drug Metab, 2011, 12(1): 57-69.
[17]	Game F. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease[J]. Nephron Clin Pract, 2014, 126(1): 14-18.
[18]	Yew T,Toh SA,Millar JS. Selective peroxisome proliferator-activated receptor-gamma modulation to reduce cardiovascular risk in patients with insulin resistance[J]. Recent Pat Cardiovasc Drug Discov, 2012, 7(1): 33-41.
[19]	Koski RR. Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus[J]. Diabetes Educ, 2006, 32(6): 869-876.
[20]	Abe M,Kikuchi F,Kaizu K, et al. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis[J]. Clin Nephrol, 2007, 68(5): 287-294.
[21]	Abe M,Okada K,Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice[J]. Curr Drug Metab, 2011, 12(1): 57-69.
[22]	Herzlinger S,Horton ES. Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes[J]. Diabetes Res Clin Pract, 2013, 100(1): 1-10.
[23]	Makino Y,Fujita Y,Haneda M. Dipeptidyl peptidase-4 inhibitors in progressive kidney disease[J]. Curr Opin Nephrol Hypertens, 2015, 24(1): 67-73.
[24]	Herman GA,Bergman A,Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes[J]. J Clin Endocrinol Metab, 2006, 91(11): 4612-4619.
[25]	Reilly JB,Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease[J]. Semin Dial, 2010, 23(2): 163-168.
[26]	Boulton DW,Li L,Frevert EU, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin[J]. Clin Pharmacokinet, 2011, 50(4): 253-265.
[27]	Inzucchi SE,Bergenstal RM,Buse JB, et al.Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J]. Diabetes Care, 2012, 35(6): 1364-1379.
[28]	Cheng D,Fei Y,Liu Y, et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: A systematic review and meta-analysis[J]. PLoS One, 2014, 9(10): e111543.
[29]	Yale J-F,Bakris G,Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease[J]. Diabetes Obes Metab, 2013, 15(5): 463-473.

Please choose a citation manager

Content to export